Active	Status	Sponsor type	Region	Phase	Filter
2 Active 1 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Moon, Sarah
ICON9, NCT03278717 / 2017-000161-75: Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients	Recruiting	3	330	Europe, Canada, RoW	Olaparib, Cediranib	University College, London, Cancer Research UK, AstraZeneca UK Limited	Ovarian Cancer	12/23	12/23
POETIC-A, NCT04584853 / 2019-003897-24: PreOperative Endocrine Therapy for Individualised Care With Abemaciclib	Recruiting	3	2032	Europe	Abemaciclib, Verzenios, Endocrine therapy (letrozole, anastrozole, exemestane or tamoxifen), Arimidex, Aromasin, Femara, or Tamoxifen	Institute of Cancer Research, United Kingdom	Breast Cancer Female	09/30	03/32
Ford, Amy
No trials found